|
Market Closed -
Other stock markets
|
Pre-market 01:42:27 am | |||
| 204.4 EUR | -1.83% |
|
206.3 | +0.93% |
| Apr. 23 | SARTORIUS STEDIM BIOTECH : Barclays reaffirms its Neutral rating | ZD |
| Apr. 22 | Sartorius Stedim: in the red with brokerage comments | CF |
Sartorius Stedim Biotech S.A. confirmed earnings guidance for the year 2022. The management confirms the outlook for the current fiscal year. Consolidated sales revenue is expected to increase by about 15% to 19%, with non-organic growth from acquisitions projected to contribute about 2% points.
The company's underlying EBITDA margin is expected to reach more than 35% this year.
| 1st Jan change | Capi. | |
|---|---|---|
| -14.66% | 21.38B | |
| -4.66% | 183B | |
| -1.01% | 108B | |
| -4.20% | 67.51B | |
| +2.68% | 50.67B | |
| +9.12% | 44.7B | |
| +3.12% | 40.95B | |
| +4.13% | 26.71B | |
| +3.31% | 26.8B | |
| +13.09% | 24.62B |
SARTORIUS STEDIM BIOTECH 
